Subscribe to access the full database, or Start Trial
Drug Name	NDC	Price/Unit ($)	Unit	Date
VOQUEZNA DUAL PAK	81520-0250-01	7.52947	EACH	2026-01-01
VOQUEZNA DUAL PAK	81520-0250-14	7.52947	EACH	2026-01-01
VOQUEZNA DUAL PAK	81520-0250-01	7.31017	EACH	2025-12-17
VOQUEZNA DUAL PAK	81520-0250-14	7.31017	EACH	2025-12-17
VOQUEZNA DUAL PAK	81520-0250-01	7.31017	EACH	2025-11-19
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Last updated: February 20, 2026

What is VOQUEZNA DUAL PAK?

VOQUEZNA DUAL PAK contains two medications: VOQUEZNA (selpercatinib) and ZOKYNL (sotorasib). It is designed for targeted cancer therapies, specifically for patients with RET-mutant non-small cell lung cancer (NSCLC) and KRAS G12C-mutant NSCLC. Market approval by the FDA occurred in July 2022, positioning the combination as a personalized treatment option for precision oncology.

What is the current market size for targeted cancer therapies?

The global oncology drug market surpassed $150 billion in 2022, with targeted therapies accounting for approximately 50% of total sales. The NSCLC segment alone approaches $30 billion annually, driven by increasing incidence and expanded indications.

Key data points:

Market value in 2022: $150 billion
Targeted therapies’ share: 50%
NSCLC segment size: $30 billion
Projected CAGR (2022-2027): 10%

How does VOQUEZNA DUAL PAK fit within the current competitive landscape?

The combination targets niche patient populations with specific mutations. Competitors include:

Drug	Indication	Approval Date	2022 Global Sales	Market Share (Est.)
XALKORI (crizotinib)	ALK, ROS1-positive NSCLC	2011	$1.7 billion	5-8%
TAGRISSO (osimertinib)	EGFR T790M-positive NSCLC	2015	$4.2 billion	15-20%
LENVIMA (lenvatinib)	Various solid tumors	2015	$2.0 billion	3-4%
VOQUEZNA (selpercatinib)	RET-mutant NSCLC	2022	Not yet established	N/A
Sotorasib (lumakras)	KRAS G12C-mutant NSCLC	2021	Estimated $600 million	N/A

VOQUEZNA is the first RET-specific targeted therapy approved for NSCLC, with no direct competitors for RET mutations. Sotorasib occupies a similar niche for KRAS G12C.

What are the price points and reimbursement landscape?

The pricing for VOQUEZNA DUAL PAK is under negotiation. However, based on current targeted therapies’ pricing, annual treatment costs range from $150,000 to $200,000.

Drug	Estimated Annual Price	Cost Components	Reimbursement Status
XALKORI	$150,000	Drug cost, administration, diagnostics	Medicare, private insurers
TAGRISSO	$180,000	Drug cost, diagnostics	Medicare, private insurers
Sotorasib (lumakras)	$125,000	Drug cost, monitoring	Medicare, private insurers
VOQUEZNA	Estimated $180,000–$200,000	Similar to other targeted therapies, diagnostics	Pending insurance negotiations

Patients with insurance coverage and national health systems generally cover 70-90% of drug costs for approved medications. High-cost drugs rely heavily on negotiated reimbursement agreements.

What are the projections for revenue growth?

Given the small initial patient population, early sales are expected to be modest. However, as clinical use expands, revenues could grow significantly.

Yearly revenue estimates:

Year	Estimated Patients (Worldwide)	Approximate Market Penetration	Projected Revenue	Notes
2023	2,000	1%	$100 million	Launch period, early adoption
2024	5,000	2%	$300 million	Growing awareness, expanded clinical use
2025	10,000	4%	$600 million	Continued uptake, pricing adjustments
2026	15,000	6%	$1 billion	Broader indications, longer-term reimbursement coverage

Key assumptions:

Rapid adoption in well-defined mutation-positive populations
Price remains stable or slightly increases with inflation
No significant disruptions in healthcare policies

What are the regulatory and market risks?

Limited data on long-term efficacy and safety could delay broader acceptance.
Pricing pressure from payers could restrict revenue growth.
Competition from potential next-generation agents or combination therapies.
Reimbursement challenges in emerging markets.

Conclusion

VOQUEZNA DUAL PAK targets a niche yet expanding segment of precision oncology. Market entry gains will depend on clinical outcomes, payer negotiations, and competitive positioning. Revenue projections are conservative initially, with potential for high growth contingent on clinical adoption and expansion of indications.

Key Takeaways

The drug enters a market with a total of roughly $150 billion in oncology sales, with targeted treatments driving growth.
Price estimates align with existing targeted therapies, ranging between $180,000 and $200,000 annually.
Revenue projections for the first three years range from $100 million to potentially over $1 billion, assuming expanding adoption.
Competitive landscape has no direct RET mutation rivals, but overlaps exist with KRAS G12C inhibitors.
Market risks include reimbursement hurdles, patient access, and evolving clinical data.

FAQs

How does VOQUEZNA DUAL PAK differ from existing treatments?
It is the first targeted therapy specifically approved for RET-mutant NSCLC, filling a niche for patients with this mutation.
What are the main factors influencing VOQUEZNA pricing?
Pricing is influenced by clinical efficacy, competitive landscape, payer negotiations, and manufacturing costs.
What is the potential market share in the next five years?
Up to 6-8% of the NSCLC targeted therapy market, assuming successful clinical adoption and reimbursement.
Are there any expected regulatory challenges?
Potential challenges include confirming long-term safety and expanding indications, which may require additional post-marketing studies.
What strategies could enhance market penetration?
Clinical education, expanding indications, and securing reimbursement agreements can increase uptake.

References

[1] Global Data. (2022). Oncology market analysis 2022.
[2] IQVIA. (2022). Global Oncology Trends.
[3] U.S. Food and Drug Administration. (2022). Drug approvals.
[4] EvaluatePharma. (2022). Oncology forecast report.

Drug Price Trends for VOQUEZNA DUAL PAK

Average Pharmacy Cost for VOQUEZNA DUAL PAK

Market Analysis and Price Projections for VOQUEZNA DUAL PAK